Quantcast
Last updated on April 16, 2014 at 7:44 EDT

Genomic Health to Present Seven New Studies at 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium

December 3, 2010

REDWOOD CITY, Calif., Dec. 3, 2010 /PRNewswire/ — Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven studies at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2010 at the Henry B. Gonzalez Convention Center. All of the studies analyze the company’s Oncotype DX® breast cancer test, which is a multi-gene expression test that physicians currently use to predict the likelihood of chemotherapy benefit and recurrence risk for women with early-stage breast cancer.

Following are details for each embargoed session (all times are in Central Standard Time):


    Friday, December 10
    -------------------

       >  Abstract: P2-09-05
      Poster Session 2 (Prognostic and Predictive Factors: Response
       Predictions - Biomarkers and Other Factors): "Risk group selection
       in primary breast cancer according to ASCO-recommended biomarkers
       of Oncotype DX and uPA-PAI-1: First experience from prospective
       multicenter WSG Plan B trial"
      Lead Author: T. Degenhardt, MD, West German Study Group
      Location: Exhibit Halls A-B
      Time: 7 a.m. - 9 a.m.

       >  Abstract: P2-09-06
      Poster Session 2 (Prognostic and Predictive Factors: Response
       Predictions - Biomarkers and Other Factors): "Meta-analysis of the
       decision impact of the 21-gene breast cancer Recurrence Score(R) in
       clinical practice"
      Lead Author: John Hornberger, MD, MS, CEO & President, Cedar
       Associates LLC and Adjunct Professor of Medicine, Stanford
       University
      Location: Exhibit Halls A-B
      Time: 7 a.m. - 9 a.m.

       >  Abstract: S4-9
      General Session 4: "Comparing the prediction of chemotherapy benefit
       in patients with node-negative, ER-positive breast cancer using
       the Recurrence Score and a new measure that integrates clinical and
       pathologic factors with the Recurrence Score"
      Presenter: Gong Tang, PhD, Assistant Professor of Biostatistics,
       University of Pittsburgh and Statistician, the NSABP Biostatistical
       Center
      Location: Exhibit Hall D
      Time: 3:15 p.m. - 5:30 p.m.

       >  Abstract: P3-10-01
      Poster Session 3 (Prognostic and Predictive Factors: Prognostic
       Factors & Biomarkers-Clinical Testing and Validation):
       "Quantitative gene expression analysis in a large cohort of
       estrogen-receptor positive breast cancers: Characterization of the
       tumor profiles in younger patients (<40 yrs) and in older patients
       (>70 yrs)"
      -------------------------------------------------------------------
      Lead Author: Steven Shak, MD, Genomic Health
      Location: Exhibit Halls A-B
      Time: 5:30 p.m. - 7:30 p.m.

       >  Abstract: P3-10-12
      Poster Session 3 (Prognostic and Predictive Factors: Prognostic
       Factors & Biomarkers-Clinical Testing and Validation): Pilot Phase
       of the Randomized Plan B Trial: Prospective Comparison of Molecular
       Classification, Oncotype DX and Clinical-Pathological
       Characteristics in Hormone-Receptor (HR) Positive Primary Breast
       Cancer
      Lead Author: Oleg Gluz, MD, West German Study Group
      Location: Exhibit Halls A-B
      Time: 5:30 p.m. - 7:30 p.m.

       >  Abstract: P3-10-13
      Poster Session 3 (Prognostic and Predictive Factors: Prognostic
       Factors & Biomarkers-Clinical Testing and Validation): "Prognostic
       value of genomic analysis after neoadjuvant chemotherapy for breast
       cancer"
      Lead Author: Erica L. Mayer, MD MPH, Staff Physician, Breast Oncology
       Center
      Dana-Farber Cancer Institute and Instructor in Medicine, Harvard
       Medical School
      Location: Exhibit Halls A-B
      Time: 5:30 p.m. - 7:30 p.m.

       >  Abstract: P3-10-15
      Poster Session 3 (Prognostic and Predictive Factors: Prognostic
       Factors & Biomarkers-Clinical Testing and Validation):
       "Quantitative gene expression by RT-PCR in classic and variant
       forms of lobular carcinoma in estrogen receptor positive invasive
       breast cancer"
      Lead Author: Joseph M. Anderson, MD, Genomic Health
      Location: Exhibit Halls A-B
      Time: 5:30 p.m. - 7:30 p.m.

About the Oncotype DX® Breast Cancer Test

The Oncotype DX breast cancer test is the first and only multigene expression test to be included in the published guidelines of both the American Society of Clinical Oncology and the National Comprehensive Cancer Network, to predict the likelihood of chemotherapy benefit as well as recurrence, for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. Additionally, physicians use Oncotype DX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes. Oncotype DX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 90 percent of U.S. insured lives provided reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions. For more information about Oncotype DX for breast cancer, please visit www.oncotypedx.com or www.untileverywomanknows.com.

About Genomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX® breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health launched its Oncotype DX colon cancer test in January 2010. As of September 30, 2010, more than 10,000 physicians in over 55 countries had ordered more than 175,000 Oncotype DX tests. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

NOTE: The Genomic Health logo, Oncotype and Oncotype DX are trademarks or registered trademarks of Genomic Health, Inc.

SOURCE Genomic Health, Inc.


Source: newswire